Synonyms: AZD-3582 | AZD3582 | HCT-3012 | NO-naproxen
Compound class:
Synthetic organic
Comment: Naproxcinod is a NO-donating naproxen analogue prodrug. It is the first in a new class of anti-inflammatory and analgesic drugs known as cyclooxygenase-inhibiting nitric oxide donors (CINODs) [2], that are designed to lessen the gastrointestinal (and cardiovascular) side-effects of traditional NSAIDs. The NO released by the prodrug mediates this beneficial effect.
|
|
No information available. |
Summary of Clinical Use |
Proof-of-concept in humans is reported in [3]. The EMA granted naproxcinod orphan designation for the treatment of Duchenne muscular dystrophy [4] in 2013, followed by the US FDA in 2015. Phase 3 studies comparing naproxcinod with naproxen or placebo in patients with osteoarthritis of the hip and knee have been completed [1,5]. |